MedPath

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Phase 3
Recruiting
Conditions
Multiple Myeloma
Interventions
Registration Number
NCT05243797
Lead Sponsor
Stichting European Myeloma Network
Brief Summary

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1594
Inclusion Criteria
  • Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.
  • Must have received only one line of therapy and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.
  • Must not be intolerant to the starting dose of lenalidomide.
  • Must not have received any maintenance therapy.
  • Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
  • Have clinical laboratory values within prespecified range.
Exclusion Criteria
  • Received any prior BCMA-directed therapy.
  • Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells).
  • Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.
  • Progressed on multiple myeloma therapy at any time prior to screening.
  • Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose.
  • Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A: Teclistamab-Lenalidomide (Tec-Len)TeclistamabTeclistamab will be administered via a subcutaneous injection (SC)
Arm A: Teclistamab-Lenalidomide (Tec-Len)LenalidomideTeclistamab will be administered via a subcutaneous injection (SC)
Arm C Teclistamab-Alone (Tec)TeclistamabTeclistamab will be administered via a subcutaneous injection (SC)
Arm B Lenalidomide Alone (Len)LenalidomideLenalidomide orally.
Primary Outcome Measures
NameTimeMethod
Progression Free Survival (PFS)from randomization to the date of disease progression or death (approximately up to 8 years)

PFS is defined as the time from the date of randomization to the date of disease progression (as assessed by IMWG criteria) or death due to any cause, whichever occurs first.

Minimal Residual Disease (MRD)-negative Complete Response (CR)at month 12

12-month MRD-negative CR is defined as participants who achieve MRD-negative status at 12 months, as determined by next-generation flow cytometry (NGF) with sensitivity of 10\^-5, prior to progressive disease or subsequent anti-myeloma therapy, whichever is earlier, and who also achieve CR of better, according to IMWG criteria.

Secondary Outcome Measures
NameTimeMethod
MySIm-Q Symptom and Impacts in Patients With Multiple Myeloma and the difference between treatment armsbaseline up to 8 years

The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.

PRO-CTCAE to evaluate symptomatic toxicities by self-report and the difference between treatment armsbaseline up to week 24

The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The PRO-CTCAE Item Library includes 124 items representing 78 symptomatic toxicities drawn from the CTCAE

Overall Survival (OS)from the date of from randomization to the date the subject's death, assessed up to 8 years]

Overall Survival (OS), measured from the date of from randomization to the date the subject's death

EQ-5D-5L health utility values and the difference between-treatment armsbaseline up to 8 years

The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today"

PGIS to evaluate the patient global impression of severity of the Multiple Myeloma and the difference between treatment armsbaseline up to 8 years

PGIS is a 1 item questionnaire that evaluates patients' health and assesses if there has been an improvement or decline in clinical status

Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment armsbaseline up to 8 years

The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

Comparison of efficacyfrom randomization to the date of disease progression or death (approximately up to 8 years)

Efficacy, assessed by rate of CR or better, MRD negative CR, sustained MRD negativity, CR and MRD negative conversion PFS after next line of therapy (PFS2), time to next treatment (TTNT), OS and also safety, PK and immunogenicity

Trial Locations

Locations (208)

LKH Hochsteiermark

🇦🇹

Vienna, Austria

The University of Arizona Cancer Center

🇺🇸

Phoenix, Arizona, United States

University of California-Davis Cancer Center

🇺🇸

Sacramento, California, United States

University of California, San Diego (UCSD) Medical Center

🇺🇸

San Diego, California, United States

University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

Colorado Blood Cancer Institute

🇺🇸

Denver, Colorado, United States

Yale New Haven Hospital

🇺🇸

New Haven, Connecticut, United States

Christiana Care

🇺🇸

Newark, Delaware, United States

Blood & Marrow Transplant Center, Florida Hospital Medical Group

🇺🇸

Orlando, Florida, United States

Moffitt at Memorial Healthcare System

🇺🇸

Tampa, Florida, United States

University of Illinois Medical Center at Chicago

🇺🇸

Chicago, Illinois, United States

Greenebaum Cancer Center UM of MD

🇺🇸

Baltimore, Maryland, United States

John Hopkins

🇺🇸

Baltimore, Maryland, United States

Clinic Ottakring

🇦🇹

Vienna, Austria

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Montefiore Medical Cente

🇺🇸

Bronx, New York, United States

Mount Sinai Medical Center - 2

🇺🇸

New York, New York, United States

Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

Duke University

🇺🇸

Durham, North Carolina, United States

East Carolina University

🇺🇸

Greenville, North Carolina, United States

Wake Forest Baptist Health

🇺🇸

Winston-Salem, North Carolina, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Oncology Hematology Care Clinical Trials

🇺🇸

Cincinnati, Ohio, United States

Seidman Cancer Center-University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Ohio State Medical Center, James Cancer Center

🇺🇸

Columbus, Ohio, United States

Lehigh Valley Health Network

🇺🇸

Allentown, Pennsylvania, United States

Penn State Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Abramson Cancer Center University of Pennsylvania Medical Center

🇺🇸

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Medical University of South Carolina (MUSC)

🇺🇸

Charleston, South Carolina, United States

Gibbs Cancer Center

🇺🇸

Spartanburg, South Carolina, United States

Vanderbilt University

🇺🇸

Nashville, Tennessee, United States

Renovatio Clinical Research

🇺🇸

The Woodlands, Texas, United States

Baylor College of Medicine Center for Cell and Gene Therapy

🇺🇸

Houston, Texas, United States

LDS Hospital/ Intermountain Healthcare

🇺🇸

Salt Lake City, Utah, United States

Virginia Oncology Associates

🇺🇸

Norfolk, Virginia, United States

St Vincent HSHS (Green Bay Oncology)

🇺🇸

Green Bay, Wisconsin, United States

University of Wisconsin Hospital and Clinics

🇺🇸

Madison, Wisconsin, United States

Froedtert Memorial Lutheran Hospital

🇺🇸

Milwaukee, Wisconsin, United States

Sunshine Coast Health

🇦🇺

Sunshine Coast, Australia

Flinders Medical Centre

🇦🇺

Adelaide, Australia

Townsville University Hospital

🇦🇺

Douglas, Australia

Barwon Health University Hospital Geelong Andrew Love Cancer Centre

🇦🇺

Geelong, Australia

Alfred Hospital

🇦🇺

Melbourne, Australia

Austin Health

🇦🇺

Melbourne, Australia

Calvary Mater Hospital

🇦🇺

Newcastle, Australia

Concord Repatriation General Hospital

🇦🇺

Sydney, Australia

Royal North Shore Hospital

🇦🇺

Sydney, Australia

Landeskrankenhaus, Feldkirch

🇦🇹

Feldkirch, Austria

Medizinische Universitaet Innsbruck

🇦🇹

Innsbruck, Austria

University Hospital Krems/Donau

🇦🇹

Krems, Austria

Kepler Universitätsklinikum Med Campus III

🇦🇹

Linz, Austria

Ordensklinikum Linz GmbH

🇦🇹

Linz, Austria

Uniklinikum Salzburg

🇦🇹

Salzburg, Austria

Medical University Of Vienna

🇦🇹

Vienna, Austria

Jessa Ziekenhuis

🇧🇪

Hasselt, Belgium

Department of Hematology, CH Jolimont

🇧🇪

La Louvière, Belgium

Algemeen Ziekenhuis Delta

🇧🇪

Leuven, Belgium

University Hospital Leuven

🇧🇪

Leuven, Belgium

Centre hospitalier universitaire de Liege

🇧🇪

Liège, Belgium

Hospital Mãe de Deus - Centro Integrado de Oncologia

🇧🇷

Porto Alegre, Brazil

Hospital Santa Rita

🇧🇷

Porto Alegre, Brazil

Instituto Americas de Ensino,Pesquisa e Inovação

🇧🇷

Rio de Janeiro, Brazil

IDOR- Instituto D'or de pesquisa. Av. São Rafael

🇧🇷

Salvador, Brazil

A Real e Benemérita Associação Portuguesa de Beneficência

🇧🇷

São Paulo, Brazil

Clínica Medica São Germano,Grupo Oncoclínicas Pesquisa Clínica

🇧🇷

São Paulo, Brazil

Departamento de Oncologia Clínica AC Camargo Cancer Center

🇧🇷

São Paulo, Brazil

Grupo Oncoclínicas Pesquisa Clínica

🇧🇷

São Paulo, Brazil

Hemocentro UNICAMP, Universidade Estadual de Campinas

🇧🇷

São Paulo, Brazil

Hospital das Clínicas da Universidade de São Paulo

🇧🇷

São Paulo, Brazil

Hospital Paulistano, Centro de Pesquisa Clinica R. Martiniano de Carvalho

🇧🇷

São Paulo, Brazil

Onco Star

🇧🇷

São Paulo, Brazil

Universidade Federal de São Paulo - Hospital São Paulo

🇧🇷

São Paulo, Brazil

Cross Cancer Institute

🇨🇦

Edmonton, Canada

QEII Health Sciences Centre

🇨🇦

Halifax, Canada

The Ottawa General Hospital

🇨🇦

Ottawa, Canada

Saskatoon Cancer Center

🇨🇦

Saskatoon, Canada

"Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)"

🇨🇦

Sherbrooke, Canada

Princess Margaret Cancer Centre

🇨🇦

Toronto, Canada

BC Cancer

🇨🇦

Vancouver, Canada

Beijing Chaoyang Hospital

🇨🇳

Beijing, China

Peking University First Hospital

🇨🇳

Beijing, China

North China University of Science and Technology Affiliated Hospital.Hematology Department

🇨🇳

Hebei, China

Shenyang City, Liaoning Province, Hematology department

🇨🇳

Shenyang, China

Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science

🇨🇳

Tianjin, China

Henan Cancer Hospital

🇨🇳

Henan, China

Shandong Qilu Hospital

🇨🇳

Shandong, China

Shanghai Fourth People's Hospital

🇨🇳

Shanghai, China

Shenzhen Second People's Hospital

🇨🇳

Shenzhen, China

The First Affiliated Hospital of Wenzhou Medical University

🇨🇳

Wenzhou, China

Tongji Hospital, Tongji Medical College of Hust

🇨🇳

Wuhan, China

Fakultni Nemocnice Hradec Kralove

🇨🇿

Hradec Králové, Czechia

Fakultni Nemocnice Ostrava

🇨🇿

Ostrava, Czechia

The First Affiliated Hospital, Zhejiang University College of Medicine

🇨🇳

Zhejiang, China

University Hospital Olomouc

🇨🇿

Olomouc, Czechia

Fakultni Nemocnice Plzen

🇨🇿

Plzen, Czechia

Vseobecna Fakultni Nemocnice V Praze

🇨🇿

Praha, Czechia

Aarhus Universitetshospital

🇩🇰

Aarhus, Denmark

Rigshospitalet

🇩🇰

Copenhagen, Denmark

Odense University Hospital

🇩🇰

Odense, Denmark

Lillebaelt Hospital

🇩🇰

Vejle, Denmark

Centre Hospitalier Universitaire De Bordeaux

🇫🇷

Bordeaux, France

Department of Hematology, CHU Lille

🇫🇷

Lille, France

Institut Paoli Calmettes

🇫🇷

Marseille, France

Centre Hospitalier Universitaire De Nantes

🇫🇷

Nantes, France

Centre Hospitalier Universitaire De Toulouse

🇫🇷

Toulouse, France

University Medical Center Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Universitaetsklinikum Heidelberg AöR

🇩🇪

Heidelberg, Germany

Universitaetsklinikum Jena KöR

🇩🇪

Jena, Germany

Universitaetsklinikum Schleswig-Holstein AöR

🇩🇪

Lübeck, Germany

Klinikum rechts der Isar der TU Muenchen AöR

🇩🇪

München, Germany

Klinikum Nuernberg

🇩🇪

Nürnberg, Germany

Centre Hospitalier Universitaire De Montpellier

🇫🇷

Montpellier, France

Hopital Saint Louis

🇫🇷

Paris, France

Hôpital Saint-Antoine

🇫🇷

Paris, France

Centre Hospitalier Universitaire De Poitiers

🇫🇷

Poitiers, France

Universitaetsklinikum Tuebingen AöR

🇩🇪

Tübingen, Germany

University Hospital of Würzburg

🇩🇪

Würzburg, Germany

University General Hospital Of Alexandroupoli

🇬🇷

Alexandroupolis, Greece

Evaggelismos Hospital

🇬🇷

Athens, Greece

Regional General Hospital Alexandra

🇬🇷

Athens, Greece

Theageneio Cancer Hospital

🇬🇷

Thessaloníki, Greece

Cork University Hospital

🇮🇪

Cork, Ireland

Beaumont Hospital

🇮🇪

Dublin, Ireland

St James's Hospital

🇮🇪

Dublin, Ireland

St Vincent's University Hospital

🇮🇪

Dublin, Ireland

University Hospital Galway

🇮🇪

Galway, Ireland

University Hospital Limerick

🇮🇪

Limerick, Ireland

The Barzilai Medical Center

🇮🇱

Be'er Sheva, Israel

Health Care Campus

🇮🇱

Haifa, Israel

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

Beilinson Hospital

🇮🇱

Petah tikva, Israel

Chaim Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Tel-Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Azienda Sanitaria Locale Al Di Alessandria

🇮🇹

Alessandria, Italy

Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi

🇮🇹

Ancona, Italy

AOU G. Baccelli

🇮🇹

Bari, Italy

Policlinico di Bari

🇮🇹

Bari, Italy

A.O. Papa Giovanni XXIII

🇮🇹

Bergamo, Italy

A.O.U. di Bologna - Policlinico S. Orsola Malpighi

🇮🇹

Bologna, Italy

A.O.Spedali Civili di Brescia

🇮🇹

Brescia, Italy

Ospedale Oncologico 'A. Businco'

🇮🇹

Cagliari, Italy

Azienda Ospedaliera-Universitaria Di Cosenza

🇮🇹

Cosenza, Italy

Careggi University Hospital

🇮🇹

Firenze, Italy

IRCCS Ospedale Policlinico San Martino

🇮🇹

Genova, Italy

IRCCS Ospedale Maggiore Policlinico

🇮🇹

Milano, Italy

Azienda Ospedaliero Universitaria Di Modena

🇮🇹

Modena, Italy

Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli

🇮🇹

Napoli, Italy

UOC Oncoematologia, Ospedale Policlinico Federico II

🇮🇹

Napoli, Italy

Azienda Ospedaliero-Universitaria Maggiore Della Carita

🇮🇹

Novara, Italy

UOC Ematologia - Azienda Ospedale - Università Padova Ospedale Giustinianeo

🇮🇹

Padova, Italy

Department of Hematology and Bone Marrow Transplant Centre, Azienda Ospedaliero - Universitaria di Parma

🇮🇹

Parma, Italy

Fondazione IRCCS Policlinico San Matteo

🇮🇹

Pavia, Italy

Azienda Sanitaria Locale Di Pescara

🇮🇹

Pescara, Italy

Ospedale Santa Maria delle Croci

🇮🇹

Ravenna, Italy

Azienda USL IRCCS Di Reggio Emilia

🇮🇹

Reggio, Italy

Ospedale "Infermi" di Rimini

🇮🇹

Rimini, Italy

Ematologia, Azienda Policlinico Umberto I

🇮🇹

Roma, Italy

Casa Sollievo Della Sofferenza

🇮🇹

San Giovanni Rotondo, Italy

A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia U

🇮🇹

Torino, Italy

Azienda Sanitaria Universitaria Giuliano Isontina

🇮🇹

Trieste, Italy

Azienda Sanitaria Universitaria Friuli Centrale

🇮🇹

Udine, Italy

Chonnam National University Hwasun Hospital

🇰🇷

Gwangju, Korea, Republic of

Department of Oncology, Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital, Internal Medicine

🇰🇷

Seoul, Korea, Republic of

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Noordwest Ziekenhuisgroep Stichting

🇳🇱

Alkmaar, Netherlands

Amsterdam University Medical Center

🇳🇱

Amsterdam, Netherlands

Albert Schweitzer Ziekenhuis

🇳🇱

Dordrecht, Netherlands

Maxima Medisch Centrum

🇳🇱

Eindhoven, Netherlands

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

Dijklander Ziekenhuis

🇳🇱

Hoorn, Netherlands

St. Antonius Ziekenhuis

🇳🇱

Nieuwegein, Netherlands

Erasmus University Medical Center Rotterdam

🇳🇱

Rotterdam, Netherlands

Maasstad Ziekenhuis

🇳🇱

Rotterdam, Netherlands

Oslo University Hospital

🇳🇴

Oslo, Norway

St. Olavs hospital HF

🇳🇴

Trondheim, Norway

Department of Hematology and Transplantology University Clinical Center

🇵🇱

Gdańsk, Poland

SPZOZ MSWiA w Poznaniu im. Prof. Ludwika Bierkowskiego, Poznań

🇵🇱

Poznań, Poland

Uniwersytecki Szpital Kliniczny

🇵🇱

Wrocław, Poland

CCAB Centro Clinico Academico Braga Associacao

🇵🇹

Braga, Portugal

Kantonsspital St. Gallen

🇨🇭

Saint Gallen, Switzerland

Champalimaud Clinical Centre

🇵🇹

Lisboa, Portugal

Sao Joao University Hospital Center

🇵🇹

Porto, Portugal

Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E.

🇵🇹

Lisboa, Portugal

Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.

🇵🇹

Porto, Portugal

Unidade Local De Saude De Gaia/Espinho E.P.E.

🇵🇹

Porto, Portugal

Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E.

🇵🇹

Vila Real, Portugal

University Clinical Center of Serbia

🇷🇸

Belgrade, Serbia

Clinical Centre of Kragujevac

🇷🇸

Kragujevac, Serbia

Clinical Centre of Nis

🇷🇸

Niš, Serbia

Clinical Centre of Vojvodina

🇷🇸

Novi Sad, Serbia

University Hospital Basel

🇨🇭

Basel, Switzerland

Inselspital

🇨🇭

Bern, Switzerland

Ankara Liv Hospital

🇹🇷

Ankara, Turkey

Ankara University Hospital

🇹🇷

Ankara, Turkey

Florence Nightingale Hospital

🇹🇷

Istanbul, Turkey

Medipol Mega University Hospital

🇹🇷

Istanbul, Turkey

Ege University Medical faculty Hospital Internal Medicine Department Adult Hematology Unit

🇹🇷

İzmir, Turkey

Izmir Economy University, Medical Point Hospital

🇹🇷

İzmir, Turkey

Erciyes University Hospital

🇹🇷

Kayseri, Turkey

Hammersmith Hospital - Imperial College NHS Healthcare Trust

🇬🇧

London, United Kingdom

University College London (UCL)

🇬🇧

London, United Kingdom

The Royal Marsden Hospital

🇬🇧

Sutton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath